Literature DB >> 20427152

Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites.

Ruchi Singh1, Dhiraj Kumar, Robert C Duncan, Hira L Nakhasi, Poonam Salotra.   

Abstract

Resistance to antimonials has emerged as a major hurdle to the treatment and control of visceral leishmaniasis (VL), also know as kala-azar (KA), the disease caused by Leishmania donovani, in India where >60% of KA patients are unresponsive to sodium antimony gluconate (SAG) treatment. Determinants of resistance in laboratory strains are partly known, however the mechanism operating in field isolates is not well understood. In microarray-based expression profiling with RNA isolated from field isolates of drug-resistant and -sensitive L. donovani parasites, genes encoding histone 1 (H1), histone 2A (H2A), histone 4 (H4), mitogen-activated protein kinase 1 (MAPK1) and two hypothetical proteins showed significantly higher expression in antimony-resistant parasites, whilst genes encoding an amino acid transporter showed higher expression in sensitive parasites. The expression level of these genes was validated by semiquantitative polymerase chain reaction (PCR). Furthermore, the higher expression of H1, H2A and MAPK1 was confirmed at the protein level in resistant isolates. Overexpression of H2A in a drug-sensitive laboratory strain as well as a field isolate of L. donovani resulted in conversion of SAG-sensitive Leishmania parasites into a resistant phenotype. Moreover, H2A overexpression resulted in a significant decrease in susceptibility towards other antileishmanial drugs currently in use, i.e. amphotericin B and miltefosine, pointing to its role in drug resistance. (c) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427152     DOI: 10.1016/j.ijantimicag.2010.03.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  26 in total

1.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

2.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 3.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

4.  Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Authors:  Arpita Kulshrestha; Vanila Sharma; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2014-01-22       Impact factor: 2.289

5.  Global genome diversity of the Leishmania donovani complex.

Authors:  Susanne U Franssen; Caroline Durrant; Olivia Stark; Bettina Moser; Tim Downing; Hideo Imamura; Jean-Claude Dujardin; Mandy J Sanders; Isabel Mauricio; Michael A Miles; Lionel F Schnur; Charles L Jaffe; Abdelmajeed Nasereddin; Henk Schallig; Matthew Yeo; Tapan Bhattacharyya; Mohammad Z Alam; Matthew Berriman; Thierry Wirth; Gabriele Schönian; James A Cotton
Journal:  Elife       Date:  2020-03-25       Impact factor: 8.140

6.  Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Authors:  Rati Tandon; Sharat Chandra; Rajendra Kumar Baharia; Sanchita Das; Pragya Misra; Awanish Kumar; Mohammad Imran Siddiqi; Shyam Sundar; Anuradha Dube
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.

Authors:  Tim Downing; Hideo Imamura; Saskia Decuypere; Taane G Clark; Graham H Coombs; James A Cotton; James D Hilley; Simonne de Doncker; Ilse Maes; Jeremy C Mottram; Mike A Quail; Suman Rijal; Mandy Sanders; Gabriele Schönian; Olivia Stark; Shyam Sundar; Manu Vanaerschot; Christiane Hertz-Fowler; Jean-Claude Dujardin; Matthew Berriman
Journal:  Genome Res       Date:  2011-10-28       Impact factor: 9.043

Review 8.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

9.  Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Authors:  Arpita Kulshrestha; Ruchi Singh; Dhiraj Kumar; Narender Singh Negi; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

10.  Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Authors:  Vasundhra Bhandari; Shyam Sundar; Jean Claude Dujardin; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.